Holen Sie sich die Stockscreener-App
5.0638
0.20%
0.0138
Amylyx Pharmaceuticals Inc Aktie (AMLX) Neueste Nachrichten
Amylyx Pharmaceuticals Inc Holds Annual Stockholder Meeting - TipRanks
DEADLINE ALERT: Bernstein Liebhard LLP Reminds Amylyx Pharmaceuticals, Inc. Investors of Upcoming Deadline - ACCESS Newswire
Amylyx gets FDA fast track status for ALS treatment - MSN
FDA fast tracks Amylyx’s ALS drug candidate AMX0114 By Investing.com - Investing.com South Africa
Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Amylyx Pharmaceuticals Receives U.S. FDA Fast Track Designation for AMX0114 for the Treatment of Amyotrophic Lateral Sclerosis - BioSpace
Amylyx Pharmaceuticals' Potential ALS Treatment Gets FDA Fast Track Designation - marketscreener.com
Amylyx (AMLX) Gains FDA Fast Track Status for ALS Treatment | AM - GuruFocus
FDA fast tracks Amylyx’s ALS drug candidate AMX0114 - Investing.com
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Shares Purchased by Millennium Management LLC - Defense World
Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Shareholders to Connect - ACCESS Newswire
Northern Trust Corp Purchases 11,214 Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World
Amylyx Pharmaceuticals (NASDAQ:AMLX) Now Covered by TD Cowen - Defense World
TD Cowen starts Amylyx stock coverage with Buy rating - Investing.com Australia
Amylyx (AMLX) Receives Buy Rating from TD Cowen on Avexitide Pot - GuruFocus
TD Cowen starts Amylyx stock coverage with Buy rating By Investing.com - Investing.com Nigeria
Amylyx (AMLX) Receives Buy Rating from TD Cowen on Avexitide Potential | AMLX Stock News - GuruFocus
Amylyx initiated with a Buy at TD Cowen - TipRanks
Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Connect - ACCESS Newswire
2025-05-29 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Connect | NDAQ:AMLX | Press Release - Stockhouse
Amyotrophic lateral Sclerosis Market 2025-2032: Top Trends & - openPR.com
🌐 ALS Treatment Market to Hit $1.04 Billion by 2032 | Driven by New Drug Approvals & Asia-Pacific Expansion - openPR.com
Man Group plc Trims Stock Position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World
Bank of America Corp DE Increases Stock Holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Shares Sold by D. E. Shaw & Co. Inc. - Defense World
Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Amylyx Pharmaceuticals to Participate in Upcoming June Investor Conferences - BioSpace
2025-05-20 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Connect | NDAQ:AMLX | Press Release - Stockhouse
Wall Street Analysts See a 105.22% Upside in Amylyx Pharmaceuticals (AMLX): Can the Stock Really Move This High? - Yahoo Finance
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives Consensus Rating of “Buy” from Analysts - Defense World
2025-05-18 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Stockholders to Learn More About the Investigation | NDAQ:AMLX | Press Release - Stockhouse
Dimensional Fund Advisors LP Acquires Shares of 54,114 Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World
Head-To-Head Survey: Perrigo (NYSE:PRGO) versus Amylyx Pharmaceuticals (NASDAQ:AMLX) - Defense World
Mizuho Boosts Amylyx Pharmaceuticals (NASDAQ:AMLX) Price Target to $8.00 - Defense World
Mizuho Adjusts Price Target on Amylyx Pharmaceuticals to $8 From $7, Maintains Outperform Rating - marketscreener.com
Amylyx (AMLX) Gets Price Target Boost Following Positive Trial Update | AMLX Stock News - GuruFocus
Amylyx price target raised to $8 from $7 at Mizuho - TipRanks
Transcript : Amylyx Pharmaceuticals, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 01 - marketscreener.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Reach Out - ACCESS Newswire
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q1 2025 Earnings Call Transcript - Insider Monkey
Hsbc Holdings PLC Lowers Holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World
Amylyx Pharmaceuticals’ Earnings Call Highlights Progress and Challenges - TipRanks
AMX0035 shows promise in Wolfram syndrome trial By Investing.com - Investing.com South Africa
AMLX Reports Promising Results from HELIOS Trial for Wolfram Syn - GuruFocus
H.C. Wainwright raises Amylyx stock target to $16 on trial hopes By Investing.com - Investing.com South Africa
H.C. Wainwright raises Amylyx stock target to $16 on trial hopes - Investing.com Australia
Amylyx Pharmaceuticals Announces Positive Long-Term Results from Phase 2 HELIOS Clinical Trial of AMX0035 in People with Wolfram Syndrome - BioSpace
Amylyx Pharmaceuticals Announces Positive Long-Term Results From Phase 2 Helios Clinical Trial Of Amx0035 In People With Wolfram Syndrome - marketscreener.com
AMX0035 shows promise in Wolfram syndrome trial - Investing.com Australia
1.30%
3.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):